PubMed Health⌕ Search

Biomedical subjects

R Cyklis

Publications and source records attributed to R Cyklis.

At least 19 recordsLinked to original sources
PubMed1995

Standard and intermediate risk acute lymphoblastic leukemia in Poland: a report of the Polish Children's Leukemia/Lymphoma Study Group.

A total of 527 children with acute lymphoblastic leukaemia (ALL) from the most frequent risk groups: standard risk group (SRG) and intermediate risk group (IRG) were treated between 1987 and 1991 according to an intensified treatment program (based on the BFM protocol) including the use of an intermediate dose of methotrexate in the IRG. A comparison of the treatment results in this group from 513 children treated between 1981 and 1987 indicates that the chance for a 6 year event-free survival has increased to 73% (previously 55%).

Antineoplastic Agents↗
PubMed1993

[Acute lymphoblastic leukemia in infants--results of treatment according to infant leukemia protocol--POG 8493].

Analysis was made of ALL treatment results according program POG 8493 in 9 infants. In 4 children WBC exceeded 100.0 G/l, and in 5 children CNS was affected. Eight infants had remission, six had relapse (mainly BM): early up to 8 month in 5, late--in 52 month in one girl. Four children died after relapse, four are still living: 2 I RC (2 and 23 months), 2 in II RC (1 month and 23 month). Probability of 4-year EFS was 0.25 and that survival--0.44. In view of continuing poor ALL prognosis, in infants it is necessary to look for more effective methods of treatment.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1992

[Second cessation of therapy in children with acute lymphoblastic leukemia].

In the group of 63 children in whom a relapse of ALL after first suspension of treatment occurred, and in whom a repeated cessation of therapy had place, 46.2% of patients had probability of a prolonged symptomless survival. The children with an isolated extramedullary relapse had a greater chance for a DFS of 7 years, than those with a relapse in the bone marrow (p = 0.05). The patients with a relapse occurring after the first cessation of treatment of ALL should be treated as intensively as newly diagnosed cases, because they have a real possibility for a prolonged survival during remission phase of disease.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1991

[The fate of children after discontinuation of treatment for acute lymphoblastic leukemia].

Among 1879 children with the diagnosis of acute lymphoblastic leukaemia made up to Dec 31 1987 in 863 cases (45.92%) treatment was discontinued. They were followed up till Dec 31 1989. The median follow-up was 3 years and 14 months. In 811 cases the treatment was discontinued during the first complete remission, in 56 cases after a relapse during initial treatment. In the time period when the programmes St. Jude and LSA2L2 were used the per cent of children with treatment withdrawal was 38.22%, but it rose to 53.01% when a more intensive programme BMF had been introduced. The probability of 7-year disease free survival after treatment discontinuation was 69.5% and 76.2% respectively. In 186 cases (21.6%) relapses developed., mostly in the first year after treatment discontinuation, but even after 7 years the risk of relapse was 2.46%. Ninety-six children (11.2%) died, 761 (88.8%) are alive, among them 671 in the first complete remission. Apart from therapy intensity, a statistically significant beneficial effect on disease free survival had discontinuation of treatment during the first complete remission, and sex--the prognosis was better in girls. In three cases secondary neoplasms were found.

Adolescent↗
PubMed1988

Long-term follow-up after relapses in children with Hodgkin's disease.

In the years 1969-1980, 68 children with Hodgkin's disease were subjected to a combined MVPP and radiotherapy. Remissions were obtained in 64 patients, and relapses occurred in 11 children. The treatment of relapse consisted in administration of B-DOPA alone or alternatively with MVPP combined with radiotherapy (in 7 out of 11 patients). The patients were recycled every 2-3 weeks which, with other modifications of chemotherapy, allowed for the completion of the six first cycles within the period of 4,5 to 7 months. A relapse caused death of one child, and two others demonstrated further relapses. At present eight children have been showing disease-free survival following a relapse for the period of 29+ to 152+ (median, 94.5 months). The authors concluded that in patients with relapses of Hodgkin's disease the decisive role rests upon aggressive chemotherapy (high frequency of cycles).

Adolescent↗
PubMed1986

Children cured of acute lymphoid leukemia. Long-term follow-up studies, including progeny.

The subject of analysis is a group of 111 children with acute lymphoid leukemia (ALL) whose remission has lasted at least 4 years since stopping treatment. Patients were observed from 4 to 18 years after ALL therapy. No symptoms of disease were observed in 110 children; one child had leukemic infiltration of the testes during the fifth year after stopping treatment. In this group of children no changes in physical development have been recorded, but a growth deficiency is sometimes noted. No symptoms of intrinsic organ lesions have been ascertained in most of the patients. All of the patients, except one with schizophrenia, lead normal lives and either attend school or go to work. Seven patients have healthy children, who were born 6-24 years after the beginning of the disease and 3-16 years after cessation of therapy.

Adolescent↗